Welcome to our dedicated page for Environmental news (Ticker: GRNA), a resource for investors and traders seeking the latest updates and insights on Environmental stock.
GreenLight Biosciences (NASDAQ: GRNA) delivers cutting-edge RNA solutions for sustainable agriculture and human health through its patented bioprocessing technology. This page provides investors and industry professionals with essential updates on the company’s scientific advancements, financial developments, and strategic direction.
Access timely press releases covering key milestones including research breakthroughs, partnership announcements, and operational updates following GRNA’s recent merger. Our curated news collection helps stakeholders track progress in mRNA therapeutics, crop protection innovations, and corporate initiatives led by CEO Andrey J. Zarur, Ph.D.
Discover updates on GRNA’s dual focus areas: RNA-based vaccines addressing critical health challenges and agricultural solutions promoting ecosystem health. The company’s status as a public benefit corporation ensures all developments align with broader environmental and social goals.
Bookmark this page for verified information about GreenLight Biosciences’ patent-protected technologies, financial performance, and industry collaborations. Check regularly for new announcements reflecting GRNA’s commitment to merging biotechnological innovation with sustainable practices.
BOSTON, May 10, 2022 – GreenLight Biosciences’ RNA-based solution for combating the Varroa destructor mite has been named a finalist for Fast Company’s 2022 World Changing Ideas Awards. This innovative approach is the first of its kind to directly target the mites, responsible for the decline of 90% of U.S. honeybee colonies. Early field trials indicate strong efficacy compared to traditional chemical methods. The solution is currently undergoing tests and is expected to seek EPA approval in 2022, highlighting GreenLight's commitment to supporting agricultural health and biodiversity.
GreenLight Biosciences has appointed Dr. Barney Graham to its Human Health Scientific Advisory Board. Dr. Graham, an influential immunologist and former deputy director of the NIAID Vaccine Research Center, is recognized for his significant contributions to vaccine development, including the first COVID-19 vaccine.
His expertise in mRNA technology and vaccine design is expected to accelerate GreenLight's efforts toward improving global health. The company focuses on RNA-based solutions for human health and agriculture and is publicly traded under the ticker GRNA.
GreenLight Biosciences has announced a licensing agreement with Serum Institute of India to create three messenger RNA products, including a shingles vaccine. This collaboration aims to enhance access to mRNA vaccines in emerging markets with a population exceeding 5 billion. Serum Institute will manage development and commercialization in these markets while GreenLight maintains rights in North America and select regions. GreenLight will receive initial payments, milestone payments, and a profit share from products sold in emerging markets, reinforcing both companies' commitment to vaccine equity.
GreenLight Biosciences has announced its agreement to operate a field research station in Spain, enhancing its research capabilities in agriculture. Located near Seville, the site will facilitate field trials for addressing crop issues such as powdery mildew and the Colorado potato beetle. The company plans to lease 10 to 20 hectares, allowing for broad-spectrum testing and efficient field work. GreenLight aims to utilize this site to advance its portfolio in both plant health and external compound integration, reinforcing its commitment to addressing agricultural challenges.
